Compositions and methods for growth factor modulation

Patent metadata

Field	Value
Publication number	US-12454570-B2
Application number	US-202318488265-A
Country	US
Kind code	B2
Filing date	Oct 17, 2023
Priority date	May 6, 2013
Publication date	Oct 28, 2025
Grant date	Oct 28, 2025

Abstract

Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins.

First claim

The invention claimed is:

1. A method of identifying an antibody, or an antigen-binding fragment thereof, that binds to human proGDF8 and inhibits GDF8 activation, the method comprising the steps of:
(i) immunizing a host with an antigen comprising a recombinant human proGDF8, wherein the proGDF8 comprises a complex comprising a GDF8 prodomain associated with mature GDF8;
(ii) carrying out a binding assay to screen for hybridoma cells that produce an antibody, or an antigen-binding fragment thereof, that binds to human proGDF8;
(iii) purifying the antibody, or the antigen-binding fragment thereof, from step (ii); and,
(iv) carrying out a growth factor activity assay to test the ability of the antibody, or the antigen-binding fragment thereof, to modulate the activity of GDF8,
thereby identifying an antibody, or an antigen-binding fragment thereof, that binds human proGDF8 and inhibits GDF8 activation.

2. A method of identifying an antibody, or an antigen-binding fragment thereof, that binds to proGDF8 and blocks activation of proGDF8, the method comprising the steps of:
(i) immunizing a host with an antigen comprising a recombinant human proGDF8 to obtain hybridoma cell lines;
(ii) screening in a binding assay for an antibody, or an antigen-binding fragment thereof, that binds to proGDF8, wherein proGDF8 comprises a complex comprising a recombinant human prodomain of GDF8 associated with mature GDF8;
(iii) testing the antibody, or the antigen-binding fragment thereof, that binds to the recombinant human proGDF8, identified in step (ii), for the ability to block activation of proGDF8 in an activation assay.

3. The method of claim 2 , wherein step (ii) comprises a binding assay selected from the group consisting of an enzyme-linked immunosorbent assay (ELISA), a surface plasmon resonance assay, and a flow cytometry assay.

4. The method of claim 2 , wherein the antibody, or the antigen-binding fragment thereof, identified in step (iii) blocks a metalloprotease cleavage of the proGDF8.

5. The method of claim 4 , wherein the metalloprotease is a BMP1/tolloid-like metalloprotease.

6. The method of claim 5 , wherein the BMP1/tolloid-like metalloprotease cleaves between residues Arg 75 and Asp 76 of the GDF8 prodomain.

7. The method of claim 2 , wherein step (iii) comprises identifying an antibody, or an antigen-binding fragment thereof, that inhibits BMP1/tolloid-like metalloprotease proteolytic cleavage between residues Arg 75 and Asp 76 of a GDF8 prodomain.

8. The method of claim 2 , wherein the activation assay in step (iii) comprises a release assay, wherein the ability of the antibody, or the antigen-binding fragment thereof, to inhibit release of mature GDF8 growth factor from the proGDF8 is measured.

9. The method of claim 8 , wherein the release assay comprises a cell-based assay or a reporter assay.

10. The method of claim 2 , further comprising a step of humanizing the antibody, or the antigen-binding fragment thereof.

11. A method for producing a pharmaceutical composition, the method comprising the step of formulating the antibody, or the antigen-binding fragment thereof, identified by the method of claim 2 and a pharmaceutically acceptable excipient.

12. The method of claim 1 , wherein step (ii) comprises a binding assay selected from the group consisting of an enzyme-linked immunosorbent assay (ELISA), a surface plasmon resonance assay, and a flow cytometry assay.

13. The method of claim 12 , wherein the antibody, or the antigen-binding fragment thereof, identified in step (iv) blocks a metalloprotease cleavage of the proGDF8.

14. The method of claim 13 , wherein the metalloprotease is a BMP1/tolloid-like metalloprotease.

15. The method of claim 14 , wherein the BMP1/tolloid-like metalloprotease cleaves between residues Arg 75 and Asp 76 of the GDF8 prodomain.

16. The method of claim 1 , wherein step (iv) comprises identifying an antibody, or an antigen-binding fragment thereof, that inhibits BMP1/tolloid-like metalloprotease proteolytic cleavage between residues Arg 75 and Asp 76 of the GDF8 prodomain.

17. The method of claim 1 , wherein the activation assay in step (iv) comprises a release assay, wherein the ability of the antibody, or the antigen-binding fragment thereof, to inhibit release of mature GDF8 growth factor from the proGDF8 is measured.

18. The method of claim 17 , wherein the release assay comprises a cell-based assay or a reporter assay.

19. The method of claim 1 , further comprising a step of humanizing the antibody, or the antigen-binding fragment thereof.

Assignees

• Scholar Rock Inc

Inventors

• Schurpf Thomas
• Mahanthappa Nagesh K
• Straub Michelle

Classifications

• C07K2317/32

  specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C12N15/1037

  Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title